ARCHIVES OF THE BALKAN MEDICAL UNION

Symptoms Sufficient to Prompt Infliximab-dose Increases in Crohn’s Disease

179 views

Dr. Geert D’Haens from Academic Medical Center, in Amsterdam, and colleagues investigated in their study of 122 patients with moderate to severe endoscopically active Crohn’s Disease (CD) if dose increases of Infliximab based on symptoms, biomarkers and/or frequently measured infliximab through level would lead to better outcomes than conventional management based on symptoms alone. The conclusion was that dose increase of infliximab for active CD based on a combination of symptoms, biomarkers, and serum concentrations was not superior to dose increase based on symptoms alone.

(https://www.medscape.com/viewarticle/891872)

Share.

About Author

Comments are closed.